Barclays PLC Pharvaris N.V. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Pharvaris N.V. stock. As of the latest transaction made, Barclays PLC holds 5,700 shares of PHVS stock, worth $105,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,700
Previous 5,700
-0.0%
Holding current value
$105,450
Previous $106,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PHVS
# of Institutions
51Shares Held
39.6MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$139 Million3.99% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.4MShares$81.4 Million53.23% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$79.4 Million65.3% of portfolio
-
Viking Global Investors LP3.65MShares$67.6 Million0.26% of portfolio
-
Vr Adviser, LLC New York, NY3.4MShares$62.8 Million6.51% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $625M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...